NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
Clinical Trials
15 trialsNCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT04521153 2025-05-11
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06796803 2025-02-10
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT04803539 2023-02-21
Artemis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Recruiting
NCT04968002 2021-07-20
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT02711007 2018-04-23
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Peking University People's Hospital
Phase 2/3 Completed
NCT02509806 2017-10-09
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
Hebei Medical University
Phase 2/3 Unknown
NCT02510469 2017-10-09
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University
Phase 2/3 Unknown
NCT03285906 2017-09-18
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02780778 2016-05-23
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT02702323 2016-03-08
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Zhejiang Cancer Hospital
Phase 2/3 Unknown
NCT02409199 2015-11-18
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT00970138 2011-07-12
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2/3 Completed